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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Is 
metformin an effective adjunct treatment in treating hirsutism in patients with PCOS?” 
 
Study Design: A review of three randomized control trials (RCTs) published in English between 
2011-2018. 
 
Data Sources: This paper evaluates three RCTs found via PubMed comparing the efficacy of 
simvastatin, clomiphene citrate and exercise as monotherapies versus each therapy in 
combination with metformin for the treatment of hirsutism in women with PCOS. 
 
Outcome(s) Measured: Hirsutism was measured using the Ferriman and Gallwey score. This 
score measures hirsutism based on the quantity and thickness of terminal hair growth in 9 
androgen-sensitive areas, including upper lip, chin, chest, upper and lower abdomen, back and 
upper arm and thigh. 
 
Results: All three studies found that adjunctive metformin did not offer a statistically significant 
increase in the reduction of hirsutism when compared to monotherapy treatments. The RCT 
performed by Banaszewska et al. showed a 1.0 point Ferriman and Gallwey score decrease when 
treated with simvastatin and metformin combination, which is not a statistically significant 
reduction when compared to the simvastatin only group, a 1.1 point decrease (p=0.52). The RCT 
performed by Roth et al. similarly showed a 1.1 point decrease when treated with clomiphene 
citrate and metformin combination, which is not a statistically significant reduction when 
compared to the clomiphene citrate only group, a 0.6 point decrease (p=0.44). The RCT 
performed by Tiwari et al. showed a 1.63 point decrease when treated with exercise and 
metformin which is also not a statically significant reduction when compared to the exercise only 
group, a 0.67 point decrease (p=0.567).  
 
Conclusions: All three studies demonstrated that the adjunctive metformin accounted for a 
decrease from the Ferriman and Gallwey score baselines, however, the decrease from baseline 
was not significantly different from the monotherapy treatment. Future studies should include 
adolescent populations, incorporate patient self-assessment data and cover a duration of 
treatment greater than six months. 
 
Keywords:   Hirsutism, PCOS, polycystic ovarian syndrome, polycystic ovaries, metformin
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INTRODUCTION: 
Polycystic ovarian syndrome (PCOS) is a condition caused by hormonal imbalance in 
which the ovaries produce increased amounts of androgens, responsible for many male 
secondary sex characteristics. The excess androgens cause many disruptions to the female body, 
including irregular menstrual cycles, acne, obesity and hirsutism.  
Hirsutism is a condition in which females acquire excessive male-pattern terminal hair 
growth in androgen-dependent areas of the body, such as the face, abdomen and chest. This 
occurs in 7% of the total female population in the United States, more than 70% of those cases 
being caused by PCOS.1 PCOS is commonly diagnosed via the Rotterdam Consensus Criteria 
that deems a patient to have PCOS if they have at least two of either clinical or chemical 
hyperandrogenism, oligomenorrhea or amenorrhea, or transvaginal ultrasound evidence of 
polycystic ovaries.2 These manifestations are accompanied by hormonal imbalances that aide in 
various hormonal changes throughout the body.  
The exact etiology of hirsutism in PCOS is unknown, however it is thought to be caused 
by a combination of insulin resistance, excess serum insulin called hyperinsulinemia and excess 
free serum androgens called hyperandrogenism. Tissues resistant to insulin cause excess free 
serum insulin that then stimulates an over production of androgens, such as testosterone. These 
excess androgens can suppress the sex-hormone binding globulin (SHBG) that is responsible for 
ridding excess serum androgens in females.4 Hirsutism occurs in the estimated fifty percent of 
women with PCOS that have androgen-sensitive pilosebaceous units, consisting of the hair 
follicle and sebaceous gland.5 These units respond to the excess androgens and stimulate male-
pattern hair growth.5 Overall, the excess insulin causes hyperandrogenism that stimulates male 
pattern hair growth, converting small, villus hairs to thicker, darker terminal hairs.4,5  
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Hirsutism is often associated with social stigmas that may cause patients to have a 
negative self-image and poor connection with their feminine identity leading to emotional 
distress.6 In a 2018 study, women reported a decreased quality of life due to the unwanted hair, 
causing limitations at work, social dysfunction and marital sexual dysfunction.6 The women with 
PCOS reported a higher presence of decreased quality of life caused by hirsutism when 
compared to idiopathic hirsutism.6 In addition to the emotional and psychological toll, a financial 
burden often becomes an issue for women that seek treatment. Most patients require a multi-
disciplinary team and a variety of both medication and procedural trials.7 A 2005 study suggests 
that $620 million is spent annually on treatment for hirsutism in women suffering from PCOS.8  
The initial suggested course of action in treating hirsutism in patients with PCOS is 
pharmacotherapy, starting with combined estrogen-progestin contraceptives.1,9 If response is not 
satisfactory, antiandrogen therapy, such as spironolactone, cyproterone acetate, drospirenone and 
finasteride may be added.9 Lifestyle changes are suggested in obese patients and have shown 
effectiveness in reducing hirsutism when an average of 5-10% body weight is lost.1,3  
The current regimens and treatments for hirsutism in PCOS patients are limited and the 
efficacy of them has not shown drastic decreases in the already formed terminal hairs, but instead 
limit the formation of new terminal hair growth, decrease coarseness of the hairs and decrease 
the rate of hair growth.9 Laser hair removal and electrolysis offer potential permanent removal of 
the terminal hair follicles and are deemed more effective for long-term treatment of hirsutism. 
Unfortunately, both options are considered more painful and typically more expensive for 
patients since they fall under cosmetic procedures and are not covered by most insurance 
companies.1,9 This results in many women resorting to temporary fixes such as tweezing, waxing 
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and shaving that can be time consuming, painful and may have a negative impact on the 
woman’s self-body image and feeling of feminitity.6 
Since hirsutism in PCOS patients is thought to be caused by hyperinsulinemia and insulin 
resistance, metformin has been suggested as an adjunctive treatment for hirsutism.2,4 Metformin 
is a medication that works by reducing glucose production from the liver and decrease intestinal 
absorption of glucose while also improving peripheral glucose uptake.4 This causes a reduction 
in hyperinsulinemia, reducing the free serum insulin that leads to the formation of excess 
androgens thought to cause hirsutism. Although metformin has been proven non-efficacious as 
monotherapy for hirsutism, it is being hypothesized that when added as adjunctive therapy, it 
may aide in the decrease of excess serum insulin and androgens, potentially further benefiting 
the patient.2,3,9   
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “Is metformin 
an effective adjunct treatment in treating hirsutism in patients with PCOS?” 
METHODS: 
 The studies used in this review were found by searching PUBMED database with the 
keywords “hirsutism”, “PCOS”, “polycystic ovarian syndrome”, “polycystic ovaries” and 
“metformin” used in the search. The studies were then selected based on their relevance to my 
question and if they included patient-oriented evidence that matters (POEM). The inclusion 
criteria restricted to only randomized control trials published after 2009. The exclusion criteria 
consisted of studies using combination treatments with oral contraceptives or insulin. Table 1 
offers additional inclusion and exclusion criteria within each individual study. All three of the 
selected studies were published peer-reviewed articles in English between the years 2011-2018. 
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The statistics used to compare and contrast the data within this review are mean change from 
baseline, standard deviation and p-value.  
This review evaluates three randomized control trials (RCTs) comparing the efficacy of 
simvastatin, clomiphene citrate and exercise as monotherapies versus each therapy in 
combination with metformin for the treatment of hirsutism. This review’s focused population is 
women over the age of 18 years old that meet PCOS diagnostic criteria. Banaszewska et al. study 
used Simvastatin 20mg daily for the control group, adding metformin 850mg twice daily as the 
intervention.2 Roth et al. study used standard clomiphene citrate treatment daily for the control 
group and added metformin 1000mg twice daily as the intervention.10 Tiwari et al. study used 
marching for 30 minutes three times weekly plus a placebo as the control group, replacing the 
placebo with metformin 850mg twice daily as the intervention.3 Both Banaszewska et al. and 
Roth et al. included a metformin only group for their comparative measures, however, that data 
was not incorporated into the interpretation of this review since metformin is being researched as 
an adjunctive therapy rather than monotherapy.2,10  
OUTCOMES MEASURED: 
 The focused outcome measured in all three studies was hirsutism via Ferriman and 
Gallwey score performed by investigators.2,3,9 This is the most common method used to quantify 
hair growth in 9 androgen-sensitive areas, including upper lip, chin, chest, upper and lower 
abdomen and back, upper arm and thigh.1  These sites are each individually scored from 0-4, 
with 0 being no hair growth and 4 being frankly virile hair growth, following male sex 
characteristics.1,9 A total score 8 or higher is deemed abnormal for female hair growth pattern in 
the United States, with lower variations for Asian populations and higher variations for 
Mediterranean populations.1,9 
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Table 1. Demographics & Characteristics of Included Studies. 
Study Type # pts Age 
(yrs) 











Met PCOS criteria 
via Rotterdam 
consensus with at 
least 2/3 of the 
following: 1) clinical 
or chemical 
hyperandrogenism 2) 
oligo- or amenorrhea 
3) polycystic ovaries 
via transvaginal 
ultrasound   
Elevated prolactin, 
thyroid disease, 
Cushing ds or 
DM.  




sensitivity or lipid 
levels within last 3 
months.  
28A -Simvastatin 




20mg/d QD PO 
and metformin 








Met criteria for 
PCOS. Women must 
be infertile. 
















Met PCOS criteria 
via Rotterdam 
consensus. Follow 
exercise schedule and 
not on any other 
regimen. 
Medical illnesses 












months prior. Pts 
who have renal or 
hepatic disorders. 
0 Marching in 
place for 30 
minutes TIW 
with placebo vs. 
marching in 
place for 30 
minutes TIW 
with Metformin 
850 mg BID 
A Losses include those from a third group not included in this review as the primary authors did not list 
data of withdraws by individual groups2,10 
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RESULTS:  
 Banaszewska et al. (2011) conducted a randomized control trial comparing the use of 
simvastatin, metformin and the combination of the two to evaluate the long-term effectiveness on 
PCOS prominent features.2 Blinding was used for randomization, however, there was not 
investigator or patient blinding of treatment due to the use of commercially marked simvastatin 
and metformin pills.2 All patients in this study fulfilled the Rotterdam consensus criteria, with 
additional inclusion and exclusion criteria data for this study is located in Table 1.2 Sixty-four 
patients were randomly assigned to either the control simvastatin only group (n=28) or 
experimental simvastatin and metformin group (n=36).2 Over the 6-month duration of this study, 
82% of patients completed the first 3 months and 70% completed the full 6 months.2 Hirsutism 
was noted in 79% of the total patients at baseline and was measured via the Ferriman and 
Gallwey scoring system at baseline, and again after 3 and 6 months of treatment.2 The 
simvastatin only treatment had a decrease in Ferriman and Gallwey score by roughly 1.1 points 
(12%) whereas the combination of simvastatin and metformin saw a decrease of 1.0 point 
(11.7%), as noted in Table 2.2 Both groups had a statistically significant decrease in hirsutism 
from their baselines, having p-values less than 0.001, however there was not a statistically 
significant difference when comparing p-values, with p-value of 0.52.2  
Table 2. Ferriman and Gallwey Score as Mean  SD Before and After Treatment.2 
 Before treatment After treatment p-value 
Control group 
Simvastatin alone 




Simvastatin and metformin 
8.7  0.3 -1.0  0.15 
(-11.7%) 
<0.001* 
*= Statistically significant (P<0.05) 
 
 Roth et al. (2012) conducted a double-blinded randomized control trial comparing the use 
of clomiphene citrate, metformin and a combination of the two to evaluate the effectiveness of 
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these treatments on improving hirsutism in PCOS patients.10 All the subjects of this study met 
the criteria for PCOS and were infertile.10 Hirsutism was noted in 81% of the patients at baseline 
and was measured via the Ferriman and Gallwey scoring system at baseline and at the 
completion of the study, whether it was ended by drop-out, pregnancy or completion of 6 cycles 
of treatment.10 Both the patients and investigators were blinded to the randomization of the 
groups and the treatment the patients were receiving.10 Three-hundred and thirty three patients 
were randomly assigned to either the control clomiphene citrate group (n=165) or experimental 
combination group (n=168).10 The clomiphene citrate only treatment decreased the Ferriman-
Gallwey score by 0.6 points while the combination of clomiphene citrate and metformin 
treatment decreased the Ferriman-Gallwey score by 1.1 points, as noted in Table 3.10 Although 
the combination of clomiphene citrate and metformin together had a statistically significant 
decrease from baseline (p<0.001), there was not a statistically significant difference when 
compared to the clomiphene alone group (p<0.024), with a p-value of 0.44.10 
Table 3. Ferriman and Gallwey Score as Mean  SD Before and After Treatment.10 
 Before treatment Mean change after treatment p-value 
Control group 
Clomiphene citrate alone 
17.3  7.1 -0.6  3.3 <0.024* 
Experimental group 
Clomiphene citrate and 
metformin 
16.8  6.1 -1.1  4.0 <0.001* 
*= Statistically significant (P<0.05) 
 
Tiwari et al. assessed the efficacy of exercise and metformin in treating hirsutism in 
patients with PCOS by conducting a double-blind placebo controlled randomized control trial.3 
All of the women in this study diagnosed with PCOS via the Rotterdam criteria, were not 
currently on an exercise regimen and had the willingness to forego 48-week long exercise plan.3  
Other further inclusion and exclusion data are listed in Table 1. Sixty-six women were divided 
into two groups of 33 women, one group receiving a placebo and the other receiving metformin 
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while both were doing the same exercise regime of 30 minutes of marching 3 times a week for 3 
months.3 Hirsutism was measured via the Ferriman and Gallwey scoring system at baseline and 
again after 3 and 6 months of treatment.3 Exercise alone decreased the Ferriman-Gallwey score 
by 0.67 points while the combination of exercise and metformin decreased the Ferriman-Gallwey 
score by 1.63 points, as noted in Table 4.3 Although the combination of exercise and metformin 
together had a significant decrease from baseline (p<0.001), it was not a statistically significant 
difference from one another when comparing their p-values (p=0.567).3 
Table 4. Ferriman and Gallwey Score as Mean  SD Before and After Treatment.3 
 Before treatment Mean change after treatment p-value 
Control group 
Exercise alone 




Exercise and metformin 
5.09  3.43 3.46  2.66 
(-1.63) 
<0.0001* 
*= Statistically significant (P<0.05) 
 
DISCUSSION: 
 This review evaluates adjunctively using metformin with currently studied treatments for 
hirsutism in PCOS patients. Each study within this review contained limitations. All three studies 
used the Ferriman and Gallwey scale which measures hirsutism in a subjective manner.2,3,10 Even 
though investigators may have been trained on proper use of the scale before the studies began, 
this method allows for human variation due to the perception and visual estimation of each 
individual patient’s hair growth. In addition, both Roth et al. and Tiwari et al. investigators knew 
that all subjects were receiving at least one type of treatment, only being blinded and concealed 
to which treatment they were receiving.3,10 Banaszewska et al. investigators and patients were 
aware of the treatment individual patients were receiving due to the use of commercially used 
pills that are identifiable to the public.2 This poses the concern for study bias amongst all three 
studies.  
Alspach, Adjunctive Metformin and Hirsutism 9 
 Another limitation is the duration of time the patients were receiving treatment. Roth et 
al. reported the study ended for patients by either pregnancy, drop out or after six consecutive 
cycles.10 Data from this study includes patient’s parameters after just one cycle of treatment 
while others received six consecutive cycles.10 Literature suggests that all initial trials of 
treatment for hirsutism should be continued for a minimum of six months before a true 
evaluation for effectiveness is completed.9 This is because six months is the approximate length 
of time of the hair follicle growth phase, offering a more accurate representation of the effects 
the treatment is having on the hair follicles themselves.9  Both Banaszewska et al. and Tiwari et 
al. completed their study after 6 months of treatment, meeting the minimum suggested time.2,3 
The patient’s satisfaction with the clinical treatment they received was not evaluated 
within any of the studies. The patient’s own assessment and perception on the effectiveness of 
their treatment would have offered an insight to the psychological impact the results had, or 
didn’t have, on the patient. In addition, between all three studies, the age demographics only 
included patients from ages 19 to 32 years old.2,3,10 Available treatments have shown positive 
effects of reducing the formation of new terminal hairs rather than ridding the ones that already 
exist.4 Thus, treatments used for reducing quantity and thickness of hirsutism may be more 
effective when started at adolescent ages, closer to the initial appearance of terminal hair and 
before the progression of the condition. 
Metformin is a relatively safe drug commonly used for type II diabetes mellitus but has 
not been approved for the use of treating hirsutism.4 There are studies that support the use of 
metformin for the treatment of other clinical manifestations in patients with PCOS, such as 
oligomenorrhea and obesity, although it is not recommended as first-line therapy due to 
collectively being less effective than current regimes.4,11 Due to the overall lack of evidence that 
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supports metformin being a superior treatment in hirsutism and other PCOS manifestations, the 
drug has not been FDA approved and any use of it clinically is considered off-label.11 
Metformin does pose some risks when taking the medication, although rare. Decreased 
B12 absorption was noted in 5-10% of patients.11 When used long term, it is suggested to 
perform annual serum B12 concentration and complete blood counts to monitor for 
megaloblastic anemia, although rare.11 Another extremely rare risk of metformin is lactic 
acidosis so consequently should be avoided in patients with a history of sepsis, congestive heart 
failure or renal insufficiency.11 It is also common for metformin to cause gastrointestinal side 
effects, such as diarrhea, abdominal pain, nausea and vomiting. Although mild and transient in 
nature, it is a frequent reason for noncompliance and/ or discontinuation of therapy.11  
CONCLUSIONS: 
All three randomized control trials in this evidence-based review did not offer supporting 
evidence that metformin is an effective adjunct treatment in treating hirsutism in patients with 
PCOS. Although all three studies demonstrated that the adjunctive metformin accounted for a 
decrease from the Ferriman and Gallwey score baselines, the decrease from baseline was not 
significantly different from the treatment groups without adjunctive metformin. Therefore, it 
would not be advised to add metformin to current regimens due to the risk side effects and 
increased pill burden without offering additional effectiveness for treatment.   
Due to the lack of grossly effective treatments for hirsutism in PCOS patient populations, 
it is encouraged to continue further research. Although metformin has not been significantly 
successful in reducing hirsutism in women with PCOS, there are recently published studies that 
assess the effectiveness of various newly considered therapies to treat hirsutism, such as vitamin 
D, prebiotics and ketogenic dieting.12,13,14 For future studies, it would be beneficial to have the 
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subjects perform self-assessments using Ferriman and Gallwey scale, in addition to the 
investigator’s, as well as having the subjects monitor their own psychological state to incorporate 
psychological measures. This would offer results on both the physical treatment of hirsutism and 
the effectiveness the treatment has on the patients’ self-image, femininity and overall quality of 
life. Also, future studies including adolescent populations may offer insight to a greater impact 
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